755 DEKA-1 a dose-finding Phase 1 trial: observing safety and biomarkers using DK210 (EGFR) for inoperable locally advanced and/or metastatic EGFR+ tumors failing systemic therapy

• Aurélien Marabelle,
• John Mumm,
• Douglas Orr,
• Alexander I Spira,
• Elizabeth C Moser,
• Deb Kientop

Affiliations

Aurélien Marabelle

Laboratoire de Recherche Translationnelle en Immunothérapie (LRTI), INSERM U1015, Villejuif, France

John Mumm

Aff114 ARMO BioSciences Redwood City CA USA

Douglas Orr

researcher

Alexander I Spira

2Next Oncology, Fairfax, VA, USA

Elizabeth C Moser

4Deka Biosciences, Germantown, MD, USA

Deb Kientop

4Deka Biosciences, Germantown, MD, USA